Last Updated: June 23, 2026

Investigational Drugs with Clinical Trials for: Leukemia, Myelogenous, Chronic, BCR-ABL Positive

✉ Email this page to a colleague

Subscribe to access the full database, or Start Trial
Drugname	Indication
TEW-7197	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Rebeccamycin	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Staurosporine	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
rimiducid	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pevonedistat	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Tipifarnib	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Camptothecin	Leukemia, Myelogenous, Chronic, BCR-ABL Positive
>Drugname	>Indication

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.